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Objective: To compare low dose sublingual misoprostol with the standard 10 IU of intramuscular oxytocin in active management 
of third stage of labor.
Materials and Methods: A total of 104 women with term pregnancy were randomized to receive either 200 µg misoprostol 
sublingually or 10 IU oxytocin intramuscularly after vaginal delivery. Primary outcome measured was mean blood loss and 
incidence of primary postpartum hemorrhage (PPH). Secondary outcome measured included duration of third stage of labor, 
side effects of drugs and need for additional oxytocics to treat life‑threatening hemorrhage. 
Results: A total of 104 women with term pregnancy in two groups of 52 were studied. The mean blood loss with sublingual 
misoprostol and oxytocin groups was 320.58 ± 244.12 vs. 253.27 ± 171.74 ml; P = 0.11. There was no significant differences 
between the misoprostol and oxytocin groups with regard to the incidence of PPH (19.2% vs. 13.5% respectively; P = 0.43). 
More women in the misoprostol group experienced side effects compared with those in oxytocin group; however, the 
difference was not statistically significant (P = 0.26). The mean duration of third stage of labor was similar and the difference 
was statistically not significant (6.65 ± 3.47 vs. 6.08 ± 3.07 minutes) (P = 0.38), as well as need for additional oxytocics 
(13.5% vs. 5.8% P = 0.18) misoprostol and oxytocin, respectively.
Conclusion: Sublingual misoprostol has similar efficacy to standard intramuscular oxytocin in preventing PPH following 
vaginal birth. Misoprostol at 200 µg with its thermostability may be an effective alternative to intramuscular oxytocin in active 
management of third stage of labor.
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Introduction
Active management of the third stage of labor (AMTSL) is 
a strategy for prevention of postpartum hemorrhage (PPH) 
which consists of interventions designed to facilitate the 
delivery of the placenta and averting uterine atony. PPH 
is still the leading cause of maternal mortality despite 
some decline in the overall mortality, an estimated 
303,000 maternal deaths occurred in 2015, a decline of 43% 
from levels in 1990.[1]
Uterine atony accounts for greater 70% of the primary PPH.[1] 
The most ideal uterotonic agent for the active management of 
third stage of labor has been the subject of research. However, 
intramuscular 10 IU of oxytocin remains the standard of care 
by the World Health Organization (WHO) recommendation.[2,3]
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Despite the preference for oxytocin, it is not always feasible to 
administer oxytocin in economically challenged environment, 
given its requirement for cool storage.[3] Carbetocin room 
temperature stable (RTS) is a new development by WHO to 
address the challenge of cold chain transport and storage 
with oxytocin; however, it also requires skilled personnel 
for parenteral administration and sterile equipment like 
oxytocin.[4] The use of oxytocin and other parenteral 
uterotonics is often restricted to urban centers. Ease of 
administration and storage with the background of its 
effectiveness, favors the use of misoprostol in communities 
of resource poor settings.[5]
The most recent Cochrane database review of misoprostol 
for third stage recognized the paucity of published work on 
lower dose of misoprostol for active management of third 
stage of labor and suggested the need for further research 
on low dose misoprostol.[6,7]
This study was a prospective randomized controlled 
comparison of a low dose 200 µg sublingual misoprostol with 
the standard 10 IU of intramuscular oxytocin for the active 
management of third stage of labor. The effect of this low 
dose regimen on postpartum blood loss and the side effects 
was compared with the standard treatment of intramuscular 
oxytocin.
Materials and Methods
The study was a randomized clinical trial carried out at the 
Department of Obstetrics and Gynaecology, Federal Medical 
Centre Owo, Ondo State, Nigeria. The study protocol was 
approved by the hospital ethical committee. The targeted 
population was booked women admitted into the labor 
room anticipating vaginal delivery and who had a singleton 
pregnancy with cervical dilatation of 6 cm or less and 
packed cell volume of at least 30%. Women in advanced 
stage	of	labor	(cervical	dilatation	>6	cm),	known	allergies	
to prostaglandins, oxytocin homologues or excipients, had 
a serious cardiovascular disorder, serious hepatic or renal 
disease, or epilepsy were not eligible. All the participants 
gave a written informed consent.
The sample size was determined using statistical formula for 
comparing two proportions with accepting a study power of 
80%, confidence interval of 95%, study/control of 1:1 and an 
acceptable dropout rate of 10%. A total of 104 subjects were 
needed to make the study statistically significant.
Women underwent randomization when vaginal birth was 
imminent. A block randomization, using computer-generated 
random numbers, was used to allocate study participants. 
A total of 104 similar opaque envelopes were used for the 
study. The envelopes were drawn to know the group into 
which a subject falls only when delivery is imminent. Women 
were randomly assigned to receive a single intramuscular 
injection oxytocin at a dose of 10 IU or 200 µg sublingual 
misoprostol immediately after the birth of the baby, the 
drug was administered and the management of the third 
stage of labor was conducted as recommended in the WHO 
guidelines.[2] Period taken from delivery of fetus to delivery 
of placenta was noted. Blood loss was measured using a 
plastic drape for blood collection (the BRASSS-V Drape), 
which was placed under the buttocks before delivery; the 
calibrated blood collection receptacle was however opened 
only after delivery of the baby, clamping and cutting of the 
cord and drainage of amniotic fluid. Blood was collected for 
1 hour but careful surveillance for further bleeding was put 
in place till 24 hours after delivery. Additional oxytocics were 
used when subsequent blood loss was adjudged excessive. 
The blood collected in the receptacle was visually noted 
and also transferred to a measuring jar and volume noted. 
Dry weight of all swabs that were used during the third 
stage were measured and noted. Blood soaked swabs were 
weighed and the dry weight of the swabs was subtracted in 
grams. Assuming an equivalence of 1 g to 1 ml, this volume 
was added to the volume of blood from the BRASSS-V drape. 
Participation in the study ended at discharge from the facility, 
transfer of the woman to a higher care unit or death. Primary 
outcomes were quantity of blood loss and incidence of PPH. 
Secondary outcomes included duration of the third stage, 
need for adjunctive uterotonics to treat life-threatening 
hemorrhage and side effects of drugs used. Obtained 
results were subjected to statistical analysis using the SPSS 
version 20. Descriptive statistics were presented using charts, 
graphs and tables as appropriate. Quantitative variables 
were described using measures of central tendencies like 
mean and median as appropriate. Association between 
qualitative variables were tested using Chi-square test, while 
associations between various quantitative variables were 
determined using the Student’s t-test and other tests as 
found appropriate. The level of significance was set at 5%. 
Ethical clearance was obtained from the institution’s ethical 
committee before commencement of the study.
Results
The total number of vaginal deliveries during 3 months study 
period was 382. A total of 104 women with term pregnancy 
in two groups of 52 each were studied. Demographic and 
base line characteristics of the two groups were comparable 
[Tables 1 and 2]. The mean blood loss with sublingual 
misoprostol and oxytocin groups was 320.58 ± 244.12 vs. 
253.27 ± 171.74 ml; (P = 0.11), [Table 3].
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The mean duration of third stage of labor was similar and the 
difference was not statistically significant (6.65 ± 3.47 vs. 
6.08 ± 3.07 minutes) (P = 0.38), as well as need for additional 
oxytocics (13.5% vs. 5.8% P = 0.18) misoprostol and oxytocin, 
respectively. There were no differences at the 5% level of 
significance between groups with regard to the incidence of 
PPH (19.2% vs. 13.5% respectively; P = 0.43), [Table 4]. Among the 
women who were recruited (safety population), the frequencies 
of the expected side effects did not differ significantly between 
the two groups [Table 5]. In misoprostol group, side effects were 
shivering, fever, nausea and abdominal pains, while the oxytocin 
group abdominal pains, headaches and shivering.
Discussion
In this randomized comparative study, we found low dose 
200 µg sublingual misoprostol and 10 IU intramuscular 
oxytocin after vaginal delivery similarly effective in active 
management of third stage of labor with comparable mean 
blood loss. Though overall blood loss with oxytocin was less, 
suggesting better efficacy; the difference was not statistically 
significant. This finding is in agreement with previous studies 
carried out in Nigeria by Afolabi et al.[5] and Oboro and 
Tabowei[8] using higher dose of misoprostol. The proportion 
of subjects in the misoprostol group who experienced PPH 
was similar to that of oxytocin. The need for additional 
oxytocics for the treatment of PPH between the two groups 
was also comparable. This finding agrees with works of 
Afolabi et al.[5] Oboro and Tabowei,[8] and Chaudhuri et al.[9] 
The use of BRASSS-V drapes also ensured a more precise 
determination of postpartum blood loss and this may have 
reduced cases that would have been erroneously regarded 
as cases of PPH.[10]
The side effect profile was similar in the misoprostol group 
compared with oxytocin group. This is consistent with 
previous studies. The noted incidence of side effects with 
misoprostol group were however lower than that of previous 
studies where higher doses of misoprostol were used.[5,8,11,12]
Availability of parenteral oxytocics for management of third 
stage of labor remains largely a hospital-based practice 
confined mostly to urban centers. WHO revealed that only 
about half of expectant mother in developing countries have 
their deliveries attended by a skilled birth attendant, and only 
about 36% deliver in health facility in Nigeria (NDHS 2013). 
In Nigeria, like other developing countries, most deliveries 
take place outside the hospital therefore making the use of 
parenteral oxytocics unlikely and even in the hospital-based 
deliveries, the challenge of maintaining cold chain for 
oxytocin is enormous.
Conclusion
Sublingual misoprostol has similar efficacy to standard 
intramuscular oxytocin in the active management of third 
stage of labor. This study also revealed that a 200 µg tablet 
may be as effective as the previously investigated higher 
doses. Thus, misoprostol at 200 µg with its thermostability 
may be an effective alternative to intramuscular oxytocin in 
active management of third stage of labor.
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Table 1: Maternal baseline characteristics













































































Gestational age (weeks) 39.43 (1.17) 39.32 (1.17) 0.45 0.66
Mean arterial blood pressure 83.53 (10.42) 81.59 (9.57) 0.98 0.33
Intrapartum packed cell volume 32.92 (2.99) 32.17 (3.13) 0.07 0.94
Table 3: Mean blood loss and mean duration of third stage of labour
Characteristics Misoprostol n=52 (±SD) Oxytocin n=52 (±SD) Mean difference (95%CI) P
Blood loss (ml) 320.58 (244.12) 253.27 (171.74) 67.30 (14.8,149.4) 0.11
Duration of third stage (min) 6.65 (3.47) 6.08 (3.07) 0.56 (0.71,1.84) 0.38
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PPH (≥500 ml) 10 (19.2) 7 (13.2) 0.63 0.43
No PPH (<500 ml) 42 (80.8) 45 (86.5)
Additional oxytocics required 7 (13.5) 3 (5.8) 1.77 0.18
Additional oxytocics not required 45 (86.5) 49 (94.2)
Table 5: Side effect profile
Characteristics Misoprostol n=9 (%) Oxytocin n=5 (%) χ2 P
Nausea 1 (11.1) 0 (0)
5.29 0.26Shivering 4 (44.4) 1 (20)
Fever 2 (22.2) 0 (0)
Headache 0 (0) 1 (20)
Abdominal pain 2 (22.2) 3 (60)
